Drugs / 99mTc-3PRGD2
99mTc-3PRGD2
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT02723760 | Nov 2015 → Dec 2018 | rheumatoid arthritis | First Affiliated Hospital of Fujian Medical University | Completed | No outcome recorded |
| Phase 0 | NCT02744729 | Oct 2015 → Jan 2017 | esophageal cancer | First Affiliated Hospital of Fujian Medical University | Completed | No outcome recorded |
| Phase 0 | NCT01737112 | Feb 2011 → Dec 2017 | lung cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03974685 | Dec 2018 → Jan 2019 | — | RDO Pharm. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04233476 | Oct 2019 → May 2021 | lung cancer, metastatic malignant neoplasm in the lymph nodes | RDO Pharm. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-3PRGD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04233476 ↗ |
| Known as | 99mTc niacinamide polyethylene glycol bicyclic RGD peptide | “Drugs use generic name：99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single” NCT03974685 ↗ |
| Known as | 99mTc-HYNIC-3PEG4-E\[c(RGDfK)2) | “This is an open-label single photon emission computed tomography / computed tomography (SPECT/CT) study to investigate the safety and diagnostic performance of...” NCT02744729 ↗ |
| Modality | Peptide | “Recently, several RGD dimeric peptides with PEG linkers have been studied. The new types of RGD peptides showed much higher in vitro integrin αvβ3-binding affinity than the...” NCT01737112 ↗ |
| Route | Intravenous | “will be intravenously injected into the patients” NCT01737112 ↗ |